Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 0.00 (0.00%)
Spread: 0.40 (0.023%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,708.60
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Bank rules force staff to turn off NHS COVID-19 tracing app at work

Thu, 08th Oct 2020 13:32

* Thousands of staff seen at risk of undetected infection -
union

* Some banks ask staff to store phones away to prevent data
leaks

* Govt advises NHS app should be paused if phone not on
person
(Adds Department of Health comment)

By Iain Withers and Sinead Cruise

LONDON, Oct 8 (Reuters) - Branch staff at some of Britain's
biggest banks say rules that require them to store phones in
lockers while at work are putting them at undue risk of COVID-19
from colleagues and customers, as they cannot use the country's
tracing app.

Lloyds Banking Group, along with rival TSB, are
among those advising employees to deactivate the NHS Track &
Trace app during office hours, when they are not allowed to keep
phones on their person.

Some banks ask staff and cashiers to store phones away to
prevent leaks of sensitive customer data, although this is not
formally required by regulator the Financial Conduct Authority.

Under current government guidelines, users of the NHS app
are advised to disable bluetooth or pause the app when away from
their phones to avoid false notifications.

Other companies have told staff to pause the app at work,
including pharmaceuticals firm GSK, which said its other
safety measures were sufficient, the Guardian newspaper
reported.

The BTU union, which represents staff working for Lloyds but
is not recognised by the bank, said it had been contacted by
dozens of staff unable to use the app, which has been downloaded
by more than 14 million people.

One unnamed Lloyds employee who contacted the BTU said: "I
live and work in a high-risk area so I am very concerned at
being told that while I'm at work I have to suspend the NHS test
and trace app... This defeats the object of track and trace."

Another said they were at risk as they had to conduct
face-to-face meetings and due to the "blatant transgression of
the social distancing rules by many customers".

"Customers and staff have a right to know if they have come
into contact with someone who's been infected," said Mark Brown,
general secretary of the BTU.

Although several European countries have launched
Bluetooth-based apps to alert those at risk of catching
COVID-19, there is little evidence to date that the technology
has significantly curbed infections.

Both Lloyds and TSB have advised staff to pause the app's
tracing function while at work, according to internal guidance
issued by each lender seen by Reuters.

"Colleagues who have downloaded the app to their own smart
phone should not use the app while you are at work," Lloyds told
staff, adding it was to stop people receiving false alerts.

A NatWest spokesman said the bank encouraged staff to use
the app but said they should pause it when they are not with
their phone. The bank discourages - though doesn't ban - the use
of personal phones in branches and contact centres.

A spokesman for Barclays said the bank had not advised staff
to turn off the app.

A Department of Health and Social Care spokeswoman said: "We
want as many people to download and use the app as possible. It
is important to use the NHS Covid-19 app at all times, including
while at work, unless in specific scenarios which are clearly
set out in our guidance."

TSB was not immediately available for comment. Lloyds
declined to comment.

A second employee union, Accord, said rules prohibiting use
of personal phones in the workplace were in place to protect
employees from security risks.

"If customers care about the health and well-being of the
bank staff they rely on, they could help by wearing face
coverings when visiting bank branches," Accord's General
Secretary Ged Nichols said.
(Reporting by Iain Withers and Sinead Cruise; Additional
reporting by Douglas Busvine in Berlin; Editing by Rachel
Armstrong, Jan Harvey and Toby Chopra)

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.